{
  "id": 19681065,
  "title": "Blackstone bets $1.5B on Pfizer’s obesity drug",
  "url": "https://urgent.news/2026/11/12/blackstone-bets-1-5b-on-pfizers-obesity-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-12T16:44:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/blackstone-pfizer-berobenatide-deal/874483/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Blackstone commits up to $1.5B for R&D of Pfizer's ex-Metsera GLP-1",
        "url": "https://urgent.news/2026/11/12/blackstone-commits-up-to-1-5b-for-r-d-of-pfizers-ex-metsera-glp-1",
        "published": "2026-11-12T11:17:18.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment",
        "url": "https://urgent.news/2026/11/12/stat-blackstone-backs-pfizers-bet-on-monthly-obesity-treatment",
        "published": "2026-11-12T16:31:10.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}